Overview

Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The study aims to investigate whether prophylaxis with liposomal amphotericin B (AmBisome®) can reduce the incidence of invasive fungal infections (IFIs) in patients with Acute Lymphoblastic Leukemia (ALL) who are undergoing their first remission induction.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Amphotericin B
Liposomal amphotericin B